ReviewCureus2026
Transcatheter Therapy in Secondary Mitral Regurgitation: Recent Clinical Evidence and Emerging Frontiers.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary mitral regurgitation (SMR) is a common valvular disorder in patients with heart failure and is associated with poor prognosis. Transcatheter edge-to-edge repair (TEER), particularly with the MitraClip device, has emerged as a less invasive alternative to surgery, with growing evidence supporting its clinical role. However, trial results have been heterogeneous, and optimal patient selection remains under debate. A narrative literature review was conducted using a targeted manual search of PubMed (2018-2026), with the terms ("secondary mitral regurgitation" OR "functional mitral regurgitation") AND (transcatheter OR MitraClip) AND (randomized OR trial OR meta-analysis). A total of 13 key studies were included, comprising randomized clinical trials, meta-analyses, and relevant prospective series, complemented by 30 selected supporting studies used for contextualization. Recent trials such as COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and RESHAPE-HF2 (Randomized Study of the MitraClip Device in Heart Failure Patients with Clinically Significant Functional Mitral Regurgitation) suggest that TEER reduces heart failure hospitalizations in selected patients, while MATTERHORN (Multicenter Mitral Valve Reconstruction for Advanced Insufficiency of Functional or Ischemic Origin) supports transcatheter repair as a safer short-term alternative to surgery in appropriate cases. The concept of disproportionate mitral regurgitation has become central to identifying candidates most likely to benefit. Alternative devices such as PASCAL (Edwards Lifesciences, Irvine, California) and emerging technologies, including transcatheter mitral valve replacement (TMVR), are expanding therapeutic options. TEER is a valuable and safe therapeutic option for patients with SMR who remain symptomatic despite optimal medical therapy, particularly when careful clinical and anatomical selection is applied. Although this review has methodological limitations inherent to its narrative design, it provides an updated and clinically relevant overview of current evidence and future directions in SMR management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.